Usual Adult Dose for Ovulation Induction

0.25 mg subcutaneously on either stimulation day 5 (morning or evening) or day 6 (morning) and continuing daily until the day of human chorionic gonadotropin (HCG) administration

Comments:

• This drug is for subcutaneous injection into the lower abdominal wall.
• When assessment by ultrasound shows a sufficient number of follicles of adequate size, HCG is administered to induce ovulation and final maturation of the oocytes. No HCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing ovarian hyperstimulation syndrome (OHSS).

Renal Dose Adjustments

Mild to moderate renal impairment: Data not available
Severe renal impairment: Contraindicated

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer via subcutaneous injection into the lower abdominal wall
• The injection site should be varied daily
• The first administration should be performed under physician supervision; the patient should be kept under medical supervision for 30 minutes after the initial injection.
• Subsequent injections may be self-administered provided that the patient is appropriately counseled

• Hypersensitivity reactions post-injection

• Vials should be refrigerated at 2 to 8 degrees Celsius and not frozen. Reconstituted product should be used immediately.

• The manufacturer's product information should be consulted.

• This drug should only be prescribed by or under the supervision of a specialist experienced with its use in the treatment of infertility.